Insider Transactions in Q1 2021 at Adaptimmune Therapeutics PLC (ADAP)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 03
2021
|
Helen Katrina Tayton Martin Chief Business & Strgy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,785,000
+49.79%
|
$0
$0.16 P/Share
|
|
Jan 19
2021
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
9,879
-42.2%
|
$49,395
$5.67 P/Share
|
|
Jan 19
2021
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
4,358
-37.24%
|
$21,790
$5.67 P/Share
|
|
Jan 19
2021
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,111
-37.36%
|
$10,555
$5.67 P/Share
|
|
Jan 12
2021
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,707
-42.28%
|
$16,242
$6.15 P/Share
|
|
Jan 12
2021
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
841
-37.6%
|
$5,046
$6.15 P/Share
|
|
Jan 12
2021
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
1,058
-37.45%
|
$6,348
$6.15 P/Share
|
|
Jan 12
2021
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,234
-37.22%
|
$13,404
$6.15 P/Share
|
|
Jan 04
2021
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,967
-42.44%
|
$24,835
$5.33 P/Share
|
|
Jan 04
2021
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
845
-37.77%
|
$4,225
$5.33 P/Share
|
|
Jan 04
2021
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,499
-37.37%
|
$17,495
$5.33 P/Share
|
|
Jan 04
2021
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
1,065
-37.7%
|
$5,325
$5.33 P/Share
|